Introduction to the Fugl-Meyer Upper Extremity Assessment

February 12, 2026

Original Air Date

On-Demand Webinar

Guest Speakers:

Becky Carr, MS, OTR/L

Senior Therapy Development Specialist
MicroTransponder Inc.

This webinar will introduce the Fugl-Meyer Upper Extremity Assessment (FMA-UE) and
highlight its value in assessing post-stroke motor impairment. Participants will learn how Fugl-Meyer findings can support candidacy determination for the Vivistim Paired VNS System and how Vivistim supports measurable gains on the FMA-UE.

* This educational session is designed to enhance understanding of the Fugl-Meyer Assessment; however, it is not a formal training and does not grant certification in administration

Topics for Discussed

Overview of the Vivistim Paired VNS System and Patient Candidacy
Introduction to the Fugl-Meyer Assessment: domains, versions, and theoretical background
Review of the Fugl-Meyer Upper Extremity Assessment (FMA-UE) outcomes from the
VNS-REHAB Trial
FMA-UE administration and scoring
practice
Live Q&A

More than one year into her transition to the neuromodulation industry, Rebecca focuses on advancing neurological care through cutting-edge technology and evidence-driven practice. Rebecca comes with a decade of clinical neuro-experience, multi-service line program management, program building, and EMR transition leadership. She thrives in multidisciplinary environments that push innovation and improve patient outcomes by thinking outside the box to enhance justification of therapy services for every neuro patient.

Watch
On-Demand Now!

Please complete this form for access to the webinar.

The MicroTransponder^® Vivistim^® Paired VNS^™ System is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment. Do not use if the patient has had a bilateral or left cervical vagotomy. Risks may include, but are not limited to pain after surgery, hoarseness, bruising, swelling, coughing and throat irritation. Infection leading to explant is a risk associated with any device surgery. For full safety information, please see www.vivistim.com/safety. Individual results may vary.